Hydroxyflutamide may not always be a pure antiandrogen [8]

Lancet

Volumn 349, Issue 9055, 1997, Pages 852-853

  Yeh, Shuyuan ^b   Miyamoto, Hiroshi ^b   Chang, Chawnshang ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; FLUTAMIDE; HYDROXYFLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

DRUG ACTIVITY; DRUG PURITY; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; LETTER; MALE; MUTANT; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030889734     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61756-4     Document Type: Article

References (5)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1992. CA-Cancer J Clin 1992; 42: 19-38.
2. Chang CS, Kokontis J, Liao ST. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324-26.
3. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-98.
4. Yeh S, Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996; 93: 5517-21.
5. Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma-flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-57.